NDA 020068 · Clinigen Hlthcare
Foscavir
Foscarnet Sodium · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Oct 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Sep 27, 1991
Approved uses
4
Original approval plus efficacy supplements
Registered trials
35
8 Phase 3, 4 recruiting
FAERS reports
1,935
1,894 serious, 702 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCAVIR. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCAVIR IS IMPERATIVE. (See ADMINISTRATION section; Hydration. ) SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCAVIR TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED. FOSCAVIR IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV INFECTIONS. (See INDICATIONS section).
What it is approved for
From the label in effect Dec 11, 2025.
INDICATIONS CMV Retinitis FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.
Mechanism: Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 1997 Supplement 6 · Efficacy
- Jan 24, 1997 Supplement 7 · Efficacy
- Jun 16, 1995 Supplement 3 · Efficacy
- Sep 27, 1991 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- FOSCAVIR · FOSCARNET SODIUM 6GM/250ML (24MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- FOSCAVIR · FOSCARNET SODIUM 12GM/500ML (24MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Foscarnet" as an intervention, any sponsor and status, largest first.
ShireTakeda (TAK)
NCT02931539 · 352 participants · Start Dec 22, 2016 · Primary completion Aug 17, 2020
Drug: Maribavir; Ganciclovir and 3 more · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 134 sites in all
- CMV Retinitis Retreatment TrialCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000766 · 300 participants · Primary completion Sep 1995
Drug: Foscarnet sodium; Ganciclovir · For: Cytomegalovirus Retinitis; HIV Infections
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 9 sites in all
- Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)Pivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00000134 · 279 participants · Start Dec 1992 · Primary completion Mar 1995
Drug: Ganciclovir; Foscarnet · For: HIV Infections; Acquired Immunodeficiency Syndrome; Cytomegalovirus Retinitis
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000665 · 240 participants · Primary completion Apr 1992
Drug: Foscarnet sodium; Ganciclovir · For: Cytomegalovirus Retinitis; HIV Infections
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 9 sites in all
- Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)Pivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00000136 · 234 participants · Start Mar 1990 · Primary completion Oct 1991
Drug: Foscarnet; Ganciclovir · For: HIV Infections; Cytomegalovirus Retinitis
- Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDSCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001061 · 167 participants
Drug: Sevirumab; Foscarnet sodium and 1 more · For: Cytomegalovirus Retinitis; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; San Jose, California · 20 sites in all
- Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)Pivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00947141 · 165 participants · Start Feb 2003 · Primary completion Dec 2011
Drug: ganciclovir (start when CMV PCR >200copies / ml x2); Stop treatment when 2 levels CMV PCR <3,000 copies / ml · For: Viraemia
Sites: London, United Kingdom
- Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised SubjectsPivotal-lookingCompleted
AiCuris Anti-infective Cures AGIndustry
NCT03073967 · 158 participants · Start May 8, 2017 · Primary completion Aug 15, 2025
Drug: Pritelivir; Investigator's choice · For: HSV Infection
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 70 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use502
- drug ineffective209
- acute kidney injury197
- pancytopenia190
- cytomegalovirus infection182
- drug resistance145
- renal impairment124
- pyrexia111
- nephropathy toxic109
- cystitis haemorrhagic100
- encephalitis cytomegalovirus99
- cytomegalovirus infection reactivation97
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 22 |
| 2006 | 25 |
| 2007 | 21 |
| 2008 | 53 |
| 2009 | 45 |
| 2010 | 35 |
| 2011 | 79 |
| 2012 | 67 |
| 2013 | 71 |
| 2014 | 60 |
| 2015 | 47 |
| 2016 | 110 |
| 2017 | 158 |
| 2018 | 149 |
| 2019 | 183 |
| 2020 | 159 |
| 2021 | 112 |
| 2022 | 98 |
| 2023 | 89 |
| 2024 | 134 |
| 2025 | 138 |
| 2026 | 61 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, et al. · Clin Infect Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.
Putera I, Ridwan AS, Dewi M, et al. · Surv Ophthalmol 2024 · Meta-Analysis, Systematic Review
- Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S, Alain S, Cervera C, et al. · J Infect Dis 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Antiviral therapy for cytomegalovirus retinitis: A systematic review and meta-analysis.
Putera I, La Distia Nora R, Dewi AC, et al. · Surv Ophthalmol 2025 · Systematic Review, Meta-Analysis
- [Cytomegalovirus polyradiculomyelopathy in AIDS].
Jayaweera DT, Cassetti LI, Espinoza L, et al. · Medicina (B Aires) 1998 · Clinical Trial, Controlled Clinical Trial
- Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation.
Ma C, Chen P, Du J, et al. · J Immunother Cancer 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Clinigen Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.